Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Insider Trading: Ex-Ariad Staffers Charged With Using FDA Info On Iclusig

Executive Summary

Former directors of pharmacovigilance and risk management agree to pay disgorgements and civil penalties in SEC complaints charging them with trading in Ariad stock in advance of FDA announcements about the leukemia drug Iclusig.

You may also be interested in...



Insider Trading By Ex-FDA Official Puts Spotlight On Agency Practices

After Office of Generic Drugs Deputy Director Gordon Johnston left FDA, he joined GPhA and 'tricked' a former colleague into sharing info on generic Lovenox on behalf of a hedge fund he was secretly working for, SEC says.

Insider Trading: Pharma Employees Increasingly In SEC Crosshairs

In past month, three individuals in biopharma space have been charged with insider trading despite efforts by companies and associations to protect confidential information; past sentencing suggests length of jail time former FDA official Gordon Johnston is likely to face.

Ariad Expects Narrower Label, Not Withdrawal, For Iclusig Following Halted Study

Company’s terminated EPIC trial in front-line leukemia was a post-marketing requirement under ponatinib’s accelerated approval for second-line treatment, but management believes FDA will favor a restricted label, rather than withdrawal, to address growing concerns about cardiovascular safety.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS120979

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel